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Pluripotent stem cell derived hepatocytes: using
materials to define cellular diﬀerentiation and
tissue engineering
B. Lucendo-Villarin, H. Rashidi, K. Cameron and D. C. Hay*
Pluripotent stem cell derived liver cells (hepatocytes) represent a promising alternative to primary tissue
for biological and clinical applications. To date, most hepatocyte maintenance and diﬀerentiation
systems have relied upon the use of animal derived components. This serves as a significant barrier to
large scale production and application of stem cell derived hepatocytes. Recently, the use of defined
biologics has overcome those limitations in two-dimensional monolayer culture. In order to improve
the cell phenotype further, three-dimensional culture systems have been employed to better mimic
the in vivo situation, drawing upon materials chemistry, engineering and biology. In this review we
discuss eﬀorts in the field, to diﬀerentiate pluripotent stem cells towards hepatocytes under defined
conditions.
1. Introduction
The advent of human pluripotent stem cells (hPSCs) and their
eﬃcient diﬀerentiation allows users to custom-make human
tissue ‘in a dish’. This has major implication in biomedicine
and will likely lead to personalised regenerative medicines of
the future. Our particular interest is in the liver, and the
generation of functional tissue from human pluripotent stem
cells. The major cell type of the liver is the hepatocyte and we,
and others,1 have been working to produce these cells at the
scale for basic research and therapeutic purposes. While freshly
isolated human hepatocytes represent the current gold stan-
dard,2,3 they are a scarce and expensive resource with variable
performance. The isolation of primary hepatocytes commences
with collagenase digestion of the liver followed by density-
gradient centrifugation.4 Post-isolation, hepatocyte phenotype
is lost and cells begin to senesce, limiting their widespread
use.5–9 In an effort to preserve the cell phenotype, a number of
approaches have been developed, including the modification of
culture media, the use of different extracellular matrices, and
the development of co-culture formats.5,7,10,11 Despite the
advantages of these approaches, phenotypic instability still
hinders the routine use of primary human hepatocytes.12 As a
consequence, alternative models have been developed to study
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human liver biology and model cell based therapy. Those
include the use of human cancer cell lines, and animal derived
hepatocytes.1 While these cell types are promising, they also
suffer from limitations which limit their routine deployment.
These include genomic instability,13 incomplete gene expres-
sion,14–17 scale-up limitation,18 heterogeneous culture and spe-
cies differences.19
While the field faces major challenges, progress is being
made. Recent studies provide hope that some of the previous
limitations associated with hepatic progenitor cell isolation
and expansion have been addressed. Hepatic progenitor cells
(HPCs), possess the capacity to regenerate liver epithelia.
Although HPCs are extremely rare in healthy liver, their scal-
ability and plasticity makes them an attractive cell source of
hepatocytes for application. Recently, Lu et al. isolated a defined
population of HPCs from the mouse liver. The resulting cells
were expandable and displayed stability following long term
maintenance in vitro and in vivo.20
Recently, the limited proliferative capacity of adult human
hepatocytes has been studied by Levy et al. The authors created an
oncostatin M dependent expansion system for primary hepato-
cytes using human papilloma virus oncoproteins.21 We have also
studied hepatocyte expansion, diﬀerentiation and stabilisation
using hPSC-derived hepatocyte-like cells (HLCs). In these experi-
ments HLC stability was maintained for over twenty days, reveal-
ing a novel gene signature associated with a stable hepatocyte
phenotype. Importantly, these findings were successfully trans-
lated to GMP grade hESC lines promising therapeutic application
in the future.22 Most recently, we have employed recombinant
laminins to drive hepatocyte diﬀerentiation and self-organisation
of HLCs from hESC lines available at GMP grade.23
We believe that the development of defined culture systems,
and novel tissue engineering processes are essential for the
delivery of stable, scalable and functional human liver tissue
and this is discussed in the review.
2. Pluripotent stem cells
Pluripotent stem cells (PSCs) are defined as cells which give rise to
all somatic cell types found in the body. Human embryonic stem
cells (hESCs) and the more recently described induced pluripotent
stem cells (iPSCs) represent the two major sources of pluripotent
stem cells (Fig. 1).24–26 Human embryonic stem cells are derived
from the inner cell mass of blastocyst stage embryos which are not
suitable for human implantation.27 Pioneering studies of mouse
ESCs28,29 and of culturing techniques developed in non-human ESC
lines30,31 and EC (embryonal carcinoma) lines32 led to the isolation
and propagation of hESC lines for the first time.27 While hESCs are
highly promising for the field, they have raised ethical issues. In
2006 and 2007 Shinya Yamanaka’s laboratory, inspired by the
successes in mammalian nuclear transfer,33 delivered a PSC popula-
tion from somatic cells, in a process called reprogramming.34,35
In these studies the authors used a core set of transcription factors
(Oct 4, Sox2, Klf4 and c-Myc) to reprogram somatic cells to a
pluripotent state. Today, PSCs serve as an important resource to
generate human tissues.
3. Transdiﬀerentiation
In addition to reprogramming, other groups have developed a
process called transdiﬀerentiation. This is the direct reprogramming
of somatic cells into another type of somatic cell, by-passing the
requirement for pluripotency.36 Traditional methods of trans-
diﬀerentiation rely on the expression of a single or a cocktail of
tissue specific transcription factors to specify somatic cell types
that are representative of all three germ layers.37–47
4. Hepatocyte diﬀerentiation
During liver development various cell types and signalling
pathways orchestrate the formation of a highly organised,
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functional and regenerative organ. The liver acinus represents
the basic functional unit of the liver. During acinar formation,
the extracellular matrix plays an important role in cell organisa-
tion and function and its composition varies depending on the
zone of the liver.48–51 Therefore, many factors must be considered
if one wishes to generate HLCs from human PSCs or from other
stem cell populations. To date, hepatocyte differentiation from
PSCs has been achieved using two different formats, either
three-dimensional cellular aggregation or two-dimensional
monolayer culture.
4.1 Hepatocyte diﬀerentiation in three dimensions
Embryoid bodies (EBs) are three-dimensional (3D) aggregates
that permit spontaneous diﬀerentiation of hPSCs in suspension,
aiming to mimic the 3D tissue niche. Seminal studies reported
by Lavon et al. demonstrated the ability to isolate and purify
HLCs using GFP under control of the albumin promoter.52
EB formation, tissue specific reporting and FACS were also
employed by Duan et al. to diﬀerentiate, purify and implant
stem cell derived hepatocytes in vivo.53 Following on from this,
Basma et al. used EB based systems to derive and enrich HLCs,
prior to their characterisation in vitro and in vivo.54 The eﬀect
of diﬀerent ECM components on hepatic diﬀerentiation has
also been studied by several groups. Schwartz et al. observed
improved endoderm gene expression in hESC-derived EBs on
type I collagen coated plates in the presence of fibroblast
growth factor 4 (FGF4) and HGF.55 Sirahashi et al. highlighted
the importance of cell maintenance media, ECM substrates,
foetal bovine serum (FBS) and growth factors in hepatocyte
diﬀerentiation.56 More recently, Vosough et al. developed a
scalable 3D diﬀerentiation approach in stirred flasks.57 While
providing a proof of concept, the presence of undefined com-
ponents in these experiments have complicated large scale
cell production and therefore application. We believe that
this highlights the need to truly define and simplify HLC
diﬀerentiation methodology for use with PSCs.
4.2 Directed hepatocyte diﬀerentiation in two dimensions
To address the issue of heterogeneous cell diﬀerentiation in
EBs, research has focused on two dimensional diﬀerentiation
systems. This requires the stepwise addition of key drivers
which move the cells from pluripotency, through definitive
endoderm to hepatic progenitors and finally functional hepa-
tocytes. Various procedures exist between labs (Table 1), but
most draw upon the seminal observations of D’Amour et al. In
these studies, hESCs were driven eﬃciently to definitive endo-
derm using activin A.58 Endoderm diﬀerentiation has also been
achieved in the presence of multiple factors including Activin A,
HGF, bone morphogenic protein 4 (BMP4), FGF2, FGF4, gluco-
corticoids, insulin and all-trans-retinoic acid (ATRA) on diﬀerent
extracellular matrices.59 TheWNT signalling pathway has also been
shown to be important in human endoderm specification.60–62
Fig. 1 Sources and properties of human pluripotent stem cells (hPSCs). hPSCs can be derived either from somatic cells isolated from the human body or
from cells isolated from the inner cell mass (ICM) of human embryos. Pluripotent stem cells possess two important attributes: the ability to self-renew
and the capacity to diﬀerentiate into any cell type in the human body. Somatic cells can be generated from pluripotent stem cells using multistep
diﬀerentition procedures or through the use of transcription factor combinations.
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Following endoderm specification, hepatic differentiation
has been achieved using a number of approaches. Cai and
coworkers developed a differentiation protocol mimicking in vivo
development using, FGF4 and BMP2 followed by HGF, OSM and
dexomethasone.63 Agarwal et al. employed FGF4 and HGF to
promote hepatic specification of hESC-derived endoderm on
type I collagen. Following this, hepatocyte differentiation and
maturation of the endoderm-derived cells were induced using a
combination of BSA, FGF4, HGF, OSM and dexamethasone.4 Hay
et al. induced hepatic progenitor specification from hESC-derived
endodermal cells by supplementing the media with 1%DMSO prior
to induction of hepatocyte differentiation in media supplemented
with HGF and OSM.65–67 Brolen et al. demonstrated hepatic speci-
fication using combinations of BMP2 and -4 with FGF1, -2 and -4,
followed by a cocktail of different factors including the epithelial
growth factor (EGF), insulin, transferrin, ascorbic acid, FGF4, HGF,
dexamethasone, dimethyl sulfoxide (DMSO) and OSM.68
Importantly, the hepatocyte diﬀerentiation procedures
developed in hESCs have been successfully translated to iPSCs.69
Song et al. reported that iPSC derived HLCs expressed liver
cell markers and related functions, including urea production,
albumin secretion and cytochrome P450 activity, which were
comparable to hESC-derived HLCs.70 Si-Tayeb et al. described
a four step diﬀerentiation protocol in low oxygen to obtain
functional HLCs with similarities to hESC-derived HLCs.71 The
diﬀerentiation protocol developed by Hay et al. was successfully
translated to iPSC technologies, with HLCs displaying metabolic
activity and secreting liver proteins.72 This was followed by
Touboul et al. who obtained hepatic progenitor cells from hESC-
derived definitive endoderm cells upon treatment with FGF10,
retinoic acid and SB431542, a pharmacological inhibitor of TGFb
signaling. Hepatocyte diﬀerentiation was induced using FGF4,
HGF and EGF.73 Following on from this, Rashid et al. developed
a three step diﬀerentiation protocol containing Activin A, BMP4
and FGF2 in the presence of glycogen synthase kinase 3b (GSK3b)
and phosphoinositide 3 kinase (PI3K) pathway inhibitors. Notably,
iPSC derived HLCs using this method were found to recapitulate key
pathological features observed in human monogenic liver disease.74
4.3 Somatic cell transdiﬀerentiation
As described previously, diﬀerentiation can be achieved with-
out the need for pluripotency. Sekiya et al. transfected murine
embryonic and adult fibroblasts with HNF4a plus FoxA1, -A2
or -A3, successfully obtaining induced hepatocytes (iHeps).79
Another seminal study, performed byHuang et al., employedmouse
tail fibroblasts as their starting cell population. Using lentivirus over-
expression of GATA4, HNF1a and Fox3 and inactivated p19Arf they
successfully generated iHeps.37 The same group recently reported
successful reprogramming of human fibroblasts into iHeps by
lentivirus expression of FoxA1, HNF1a and HNF4a. The resulting
iHeps displayed hepatic function80 and excitingly fueled a bio-
artificial liver device that improved animal survival followed by
acute liver failure.81 Therefore, iHeps andHLCs represent a reliable
alternative to primary human hepatocytes, holding great
potential for biological and clinical applications. These cells
have been employed to accurately predict human drug meta-
bolism and drug responses,82–84 as a model to study hepatitis C
and B viral life cycle,85–89 to study the mechanisms behind the
drug-induced liver injury90,91 and to modulate drug overdose
by using non-coding RNAs.67 However, improvements in cell
fidelity are required.92 One key void in current approaches is
the niche for driving cell differentiation and maintaining the
cell phenotype. This is an important area of focus which
requires interdisciplinary research.22
5. Biomaterials in stem cell biology
Traditionally, hPSCs were cultured on murine embryonic fibro-
blast layers or extracellular matrices derived from mice, such
Table 1 Step-wise diﬀerentiation of human embryonic stem cells and induced pluripotent stem cells through definitive endoderm with Activin A (AA) to
hepatocytes
Substrate Definitive endoderm induction Hepatic specification Hepatic diﬀerentiation Ref.
MEFs AA (3d) FGF4, BMP2 (5d) HGF (5d) + OSM (5d) Cai et al., 200724
MEFs/collagen I AA, FBS, KOSR (5d) FGF4, HGF, KOSR (3d) BSA, FGF4, HGF, OSM, Dex (2d) +
FGF4, HGF, OSM, Dex (9d)
Argawal et al., 200864
Matrigel AA, Wnt3a (3d) 1% DMSO, 20% KOSR (5d) HGF, OSM (9d) Hay et al., 200865
MEFs AA, FGF2 (5d) BMP 2/4, FGF1/2 (11d) EGF, insulin, hydrocortisone,
transferrin (28d)
Brolen et al., 200968
MEFs AA, bFGF (3d) HGF, DMSO (8d) Dex (3d) Basma et al., 200954
Matrigel AA (5d) FGF4, BMP2 (5d) HGF (5d) + OSM (5d) Si-Tayeb et al., 201071
Matrigel AA, Wnt3a, (3d); +AA (2d) 1% DMSO, 20% KOSR (5d) OSM, HGF (5d) Sullivan et al., 201072
Matrigel AA, BMP4,FGF2 (3d) FGF10 (3d) FGF4, HGF, EGF (8d) Toboul et al., 201073
Fibronectin AA, FGF2, BMP4, Ly294002,
CHIR99021 (1d) + AA, FGF2,
Ly294003 (1d)++AA, FGF2 (1d)
AA (5d) HGF, OSM (17d) Rashid et al., 201074
MEFs AA, Wnt3a, HFG (3d) 1% DMSO, 20% KOSR (5d) OSM/HGF (7d) Chen et al., 201275
Matrigel AA, Wnt3a (3d) 1% DMSO, 20% KOSR (5d) HGF, OSM (9d) Szkolnicka et al., 2014;76
Rashidi et al., 201677
Matrigel AA, Wnt3a, HFG (3d) 1% DMSO, 20% KOSR (5d) OSM, FGF2, insulin, Dex (7d) +
OSM, FGF2, insulin, Dex, LCA,
MK4 (4d)
Avior et al., 201578
Laminin AA, Wnt3a (3d) 1% DMSO, 20% KOSR (5d) HGF, OSM (9d) Cameron et al., 2015 et al.23
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asMatrigel. However, the undefined nature of these environments,
along with the potential pathogenic and immunogenic issues,
is known to be problematic for clinical application and serves
as a barrier to reproducible cell based modelling. In an attempt
to overcome these limitations, research studies have focused on
developing xeno-free and defined substrates that can eﬃciently
replace the use of animal-derived culture components.23,93–96
In an attempt to reduce the costs associated with cellular
differentiation, attention has also focussed on developing
cheap synthetic substrates for PSC maintenance and differen-
tiation (Fig. 2).
5.1 Synthetic polymers
Biomaterials can be defined as a material or a combination of
materials that can be used to support cells, tissues or organs
in vitro and in vivo. According to their make-up, biomaterials can
be classified as polymers, metals, ceramics and composites.
Natural and synthetic polymers have gained the attention of
researchers in the stem cell field due to their inert nature,
diverse composition, capacity to interact with other synthetic
or natural substrates, and reliable cost-eﬀective scale-up.
Combinatorial approaches involving the use of synthetic
polymers and biologics have been employed in the maintenance
and diﬀerentiation of hPSCs with promising results. For example,
polymers with high acrylate content combined with vitronectin
have been reported to successfully maintain the pluripotency
properties and colony formation of PSCs for a prolonged period
of time.97 In addition, to support hPSC maintenance, combi-
natorial polymer screens have led to the development of
hepatic diﬀerentiation or co-culture strategies.98–100 Examples
of successful application of biomaterials in the formation
of organoid cultures, include the improved expression of hepa-
tocyte growth factor mRNA with faster formation of viable
3D spheroids following co-culture of hepatocytes with stellate
cells on a PLGA substrate.101 Increased albumin secretion has
also been achieved following the manufacture of endothelia-
lized hepatic spheroids in PDMS honeycomb microwells and
poly-L-lactide fibers.102 However, batch-to-batch variation, the
risk of pathogens from undefinedmedia components and the high
cost associated with the production of some biologics compromise
technology scale up and application.105 Therefore, to deliver somatic
cells under defined conditions research has focussed on cheap
and scalable synthetic materials and renewable cell sources.
Poly [2-(methacryloyloxy) ethyl dimethyl-(3-sulfopropyl)
ammonium hydroxide] (PMEDSAH) is a well-characterised syn-
thetic substrate employed in the maintenance of PSCs. It is
thought that the sulfonic group mimics heparin sulphate
proteoglycans, which are important extracellular components
in hPSC culture systems99,103–106 and mesenchymal stem cells
derived from hPSCs.107 Aminopropylmethacrylamide (APMAAm)
represents another example of a synthetic substrate successfully
employed in the long-term maintenance of undifferentiated
PSCs, by promoting the adsorption of different proteins present
in the culture media.108 The importance of media protein
adsorption in the maintenance of PSCs was also revealed by
Mei et al., by identifying a polymer generated from monomers
with high acrylate content, displaying the capacity of fixing
vitronectin from the culture media and promoting colony
formation. This system also revealed the importance of physical
parameters of the polymers including wettability, surface topo-
graphy and surface chemistry.97
5.2 3D culture systems
Synthetic polymers have been proven to be economical and
eﬀective for the long-term self-renewal, large-scale expansion
and direct diﬀerentiation of hPSCs. However, these platforms
are traditionally applied in two-dimensional (2D) systems.
Although 2D systems have proved to be invaluable for studying
basic cell biology, cells in these systems are forced to change their
cytoskeleton towards flattened shapes, aﬀecting cell-to-cell and cell-
to-extracellular environment contacts. These forces lead to reduced
polarisation and modification of important signalling pathways,
aﬀecting stem cell pluripotency and diﬀerentiation.109 As a con-
sequence diﬀerent approaches have been employed to emulate 3D
tissue structure. These approaches can be broadly divided into
scaﬀold-based and scaﬀold-free culture systems (Fig. 3).
Fig. 2 Evolution of human pluripotent stem cell culture and diﬀerentiation. Culture conditions are becoming increasingly defined, reducing cell
variability and scale-up costs. The field has moved away from animal feeder layers, using undefined ECM formulations, such as Matrigel. As Matrgiel is an
undefined mixture of murine proteins and growth factors, the field has now moved toward recombinant proteins and/or synthetic substrates to support
hPSC culture and diﬀerentiation.
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5.2.1 Scaﬀold-based culture systems. Scaﬀold-based systems
rely on the presence of natural or synthetic materials to provide a
3D space for cell attachment. These systems allow the production
and organization of cells in vitro in a controllable and reproducible
manner which is important for routine cell culture. Several
materials of synthetic origin have been employed for hPSC main-
tenance and diﬀerentiation in 3D. Hydrogels are an example.
Hydrogels are structures composed of cross-linked and hydrophilic
polymer units that swell when exposed to water, allowing fine
tuning in two or three dimensions. Moreover, hydrogels support
the encapsulation and controlled release of bioactive agents and
have been used successfully as hPSC culture substrates.108,110,111
Of note, Zhang et al. identified a thermoresponsive acrylate-based
hydrogel for themaintenance enzyme free scale-up of hPSCs under
defined conditions.112 Although hydrogels can mimic more closely
the native 3D environment, the limited diﬀusion rate of nutrients
within the structure can restrict cell type compatibility and long-
term cell culture, necessitating cell compatibility testing.113
Natural hydrogels have also been employed for cell culture.
Alginate, a polysaccharide derived from the cell wall of marine algae,
is one example and has been used to successfully culture hepato-
cytes in 3D. Interestingly, cell aggregation, essential to ensure correct
cell function, was mediated by E-cadherin.114 In another study, Fang
et al. demonstrated that exogenous growth factors were required for
hepatocyte diﬀerentiation via EBs in alginate microbeads.115 More
recently, Jitraruch et al. described an intraperitoneal transplantation
of alginate-microencapsulated human hepatocytes in a murine
model that reduced the severity of liver damage.116
5.2.2 Scaﬀold-free culture systems. In contrast to scaﬀold-
based culture systems, scaﬀold-free culture systems rely on the
self-aggregation of the cells. In hepatocyte biology, tight cell-to-cell
contact is important to ensure cell polarisation.46 Bioreactors, one
of the most studied suspension culture systems, are widely used in
chemical and biological industries. In recent years this technology
has been translated to the stem cell field, with designs controlling
and regulating the cellular microenvironment to support self-
renewal and specification of cells. Bioreactors include, rotary
cell culture systems and stirred-suspension systems, to create a
uniform and dynamic environment for cells.
There are several examples of the scaﬀold-free culture system
applied in hPSC technology. Amit et al. developed serum free
suspension culture methodology using an IL6R-IL6 (interleukin-6
receptor interleukin-6) fusion protein supporting to support cell
expansion and pluripotency.117 Steiner employed an alternative
approach supporting suspension cultures of hPSCs using neurobasal
media supplemented with serum replacement and diﬀerent ECM
components.118 More recently, Vosough et al. described a stirred-
suspension bioreactor culture to obtain iPSC-derived HLCs that
post-transplantation supported mice with acute liver damage.57
6. Current challenges and future
directions
Although current diﬀerentiation approaches from pluripotent
stem cells generate HLCs displaying hepatocyte markers and
Fig. 3 Culture system physical properties. The physical environment of pluripotent and diﬀerentiated cells has also evolved; from static 2D culture to 3D
culture systems. Static 2D cultures do not accurately mimic the in vivo environment and frequently result in alterations in cell biology. 3D culture systems
can be divided into scaﬀold-based and scaﬀold-free systems. 3D stirred-suspension cultures represent a more advanced culture system, with cells
homogeneously exposed to the diﬀerent factors in the medium. Further research and development is required in this space to permit cost eﬀective
technology scale up.
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function, they still express features of foetal hepatocytes. In
support of this, Godoy et al. compared gene regulatory networks
between pluripotent stem cell derived HLCs and adult human
hepatocytes. In comparison to PHHs, HLCs expressed the
majority of hepatic genes (B70%). However, there were many
genes which did not approach the levels of primary hepatocytes
(B30%). They also identified the expression of colon, fibroblasts
and stem cell-associated transcription factors, indicating mixed
HLC cultures in vitro.92 These studies concluded that in vitro
culture conditions for primary hepatocytes and HLCs were
responsible for their instability and/or not reaching a fully diﬀer-
entiated status. Importantly, those studies provided a ‘blue-print’
to help eliminate non-desired cell traits.
Liver development is a process that extends beyond birth,
when there is a switch from placental to enteral nutrition.
Fatty acids from breastfeeding become the main energy source,
and those are further metabolised by the gut microbiome to
secondary metabolites, which lead to liver development in the
neonate. In line with this, Avior et al. recently demonstrated
that a secondary metabolite, lithocholic acid (LCA), or the
use of Vitamin K may drive maturation of HLCs. They demon-
strated that these additives synergise, regulating the activity
of a key nuclear factor, PXR, improving cytochrome P450
enzymes 2C9 and 3A4 expression and function.127 While
promising, stem cell derived HLC cultures generated using this
method are short lived, limiting technology scale up and
application.
Searching for defined matrices compatible with mainte-
nance of pluripotency and diﬀerentiation capacities of pluripo-
tent stem cells has been traditionally slow and has shown low
throughput. However, in recent years, high-throughput (HTP)
approaches such as microarraying have allowed rapid screening
of chemically diverse substrates that modulate or control cell
biology, thus representing an important tool for discovering new
materials. HTP technologies have identified polymers with trap-
ping and release properties119 for cell isolation, proliferation and
diﬀerentiation.120 Recently, Celiz et al. demonstrated that polymer
high-throughput screening technology could be used to identify
polymer(s) that support stem cell self-renewal and stem cell
diﬀerentiation to cells representative of the three germ layers.
They identified a polymer (HPhMA-co-HEMA), which resulted from
the polymerization of 5 (N-(4-hydroxyphenyl)methacrylamide)
and poly (2-hydroxyethyl methacrylate) (polyHEMA), supporting
both hPSC culture and pluripotency in a defined environment.121
In a separate study a synthetic polyurethane, PU134, was identi-
fied employing HTP technology100 and facilitated the maturation
and maintenance of HLCs from research and GMP grade hESC
lines.22
Concerning the cell niche, most current diﬀerentiation
approaches lack many aspects of the micro-environment. There-
fore the development of strategies employing relevant cell
types from the organ of interest in 3D is required. In this vein,
Takebe et al. developed an innovative approach. Endothelial
and mesenchymal cells, in combination with PSC-HLCs, self-
organised into 3D liver-like tissue structures which were func-
tional in vitro and in vivo. Moreover, the authors demonstrated
liver function could be supplied from the mesentery, represent-
ing an ideal target site for future cell based therapies.122
The emergence of bioprinting in the recent years has also
provided new opportunities for the production of printed
human liver tissue. Recently Organovo’s exVive3D bioprinted
liver tissue (Organovos; USA) has been shown to secrete
fibrinogen, albumin and transferrin in proportion to levels
observed in vivo.123 Regarding PSCs, valve-based cell printers
have been developed to print viable PSC and HLC populations,
and oﬀer the promise of automated tissue manufacture for
clinical and research applications.124
A common problem associated with most diﬀerentiation
systems is their static nature. These approaches lack fluid
circulation resulting in poor cell perfusion. Recently, Giobbe
et al. reported a microfluidic system on a chip to diﬀerentiate
PSCs into HLCs which could predict drug toxicity.125 Addition-
ally, Berger et al. described a successful microfluidic system
employing co-cultures of PSC-derived HLCs and stroma cells,
reporting enhanced maturity and polarity.126 More recently, we
have shown that pluripotent stem cell-derived HLCs can be
further improved by exposing them to fluid shear stress.77
In conclusion, the ability to derive somatic cell types from
hPSCs represents an attractive strategy for human tissue engi-
neering. Despite promising advances in the field, further
sophistication is necessary to improve cell type fidelity and
stability. To date, diﬀerentiation protocols are mainly per-
formed using 2D culture systems lacking the relevant cell types.
Recent progress in the field, including; combinatorial
approaches and three-dimensional and co-culture strategies
provide the promise of more sophisticated systems in the
future.
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